After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order
China’s leading provider of outsourced medical services said its profit and revenue rose 48.4% and 30% last year, respectively, marking a significant slowdown from the previous yearKey Takeaways:WuXi Biologics revenue…
RELATED ARTICLES
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG -
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
FAST NEWS: WuXi Biologics boosts new projects target
2269.HK
-
FAST NEWS: WuXi XDC kicks off IPO with star cornerstone investors
2269.HK
-
FAST NEWS: JPMorgan boosts WuXi AppTec stake
2359.HK 603259.SHG
